US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Chronic kidney disease (CKD) is a growing global health concern, significantly contributing to morbidity and mortality rates worldwide. Characterized by a ...
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback